Growth Hormone Fragment / Lipolytic Research Peptide
HGH Fragment 176-191 (GH Frag) Research Peptide
HGH Fragment 176-191 is a synthetic 16-amino acid peptide corresponding to positions 176–191 of the 191-amino acid human growth hormone (hGH) sequence. This C-terminal region of hGH has been characterized in preclinical research as a domain involved in lipolytic activity, and it is studied separately from intact GH because it is considered to lack the anabolic and insulin-antagonistic properties associated with full-length growth hormone.
Compound identity
- Name
- HGH Fragment 176-191
- Class
- Growth Hormone Fragment / Lipolytic Research Peptide
- CAS number
- 221231-10-3
- Molecular formula
- C₇₈H₁₂₃N₂₃O₂₃S₂
- Also known as
- GH Frag 176-191, Growth Hormone Fragment 176-191, HGH Frag, Fragment 176-191
- Sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (aa 176–191 of hGH, 16 residues; Cys182–Cys189 disulfide bridge; MW ~1817 Da)
Research context
Human growth hormone (hGH, somatotropin) is a 191-amino acid polypeptide secreted by somatotroph cells of the anterior pituitary. Structure-activity relationship research on hGH identified that distinct regions of the molecule mediate different biological activities. The C-terminal fragment spanning residues 176–191 (CAS 221231-10-3, MW ~1817 Da, C₇₈H₁₂₃N₂₃O₂₃S₂) contains a Cys182–Cys189 disulfide bridge and has been characterized in preclinical models as retaining lipolytic signaling properties without activating the canonical GH receptor dimerization mechanism that drives anabolic and insulin-antagonistic effects of full-length hGH. This peptide is distinct from AOD-9604 — a related but separately developed analog that spans an overlapping region with a C-terminal amide modification and modified N-terminus.
Preclinical research with HGH Fragment 176-191 has primarily examined adipocyte lipid metabolism. Studies in rodent models reported effects on fat oxidation pathways, including proposed involvement of β3-adrenergic receptor-dependent mechanisms in adipose tissue. The fragment is used as a pharmacological tool to probe which structural elements of hGH drive lipolytic versus anabolic signaling, and to study GH-receptor-independent lipid mobilization pathways. Research has compared its activity profile to both intact hGH and to the modified analog AOD-9604.
As a research reagent, HGH Fragment 176-191 is used in adipocyte biology, growth hormone structure-function studies, and lipid metabolism research. DMV Research supplies it as a lyophilized peptide with per-batch Certificate of Analysis confirming identity by mass spectrometry and purity ≥99% by HPLC.
Frequently asked questions
What is HGH Fragment 176-191?+
HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the 191-residue human growth hormone sequence. This 16-amino acid C-terminal region of hGH has been characterized in preclinical research as contributing to the lipolytic signaling properties of GH. The peptide is studied to investigate hGH structure-function relationships and fat metabolism signaling pathways.
What is the difference between HGH Fragment 176-191 and AOD-9604?+
Both compounds derive from the C-terminal region of human growth hormone and are studied for their lipolytic properties, but they are distinct molecules. HGH Fragment 176-191 is the unmodified native hGH sequence peptide (residues 176–191). AOD-9604 is a separately developed analog covering a partially overlapping region (approximately residues 177–191) with a C-terminal amide modification designed to improve stability. The two compounds have different CAS numbers (221231-10-3 vs. AOD-9604) and are studied as distinct research reagents, though their preclinical activity profiles overlap in lipolytic research contexts.
Does HGH Fragment 176-191 activate the GH receptor?+
Preclinical research indicates that the 176-191 fragment does not activate the GH receptor in the same manner as intact hGH — it lacks the N-terminal domain required for canonical GH receptor dimerization and downstream IGF-1 stimulation. Its proposed lipolytic activity in rodent models is under investigation via alternative mechanisms including β3-adrenergic receptor involvement in adipose tissue. These mechanistic details remain active areas of preclinical research.
Is HGH Fragment 176-191 approved for human use?+
No. HGH Fragment 176-191 is not approved by the FDA or any regulatory body for human use. As supplied by DMV Research, it is a research peptide for in-vitro and pre-clinical laboratory research purposes only. Not for human consumption.
Research use only
All products are intended for laboratory and research use only (RUO) and are not for human consumption, ingestion, or any in-vivo use.
The statements on this page have not been evaluated by the FDA. HGH Fragment 176-191 is not intended to diagnose, treat, cure, or prevent any disease. Content is provided for laboratory research reference only.